PARTICIPA

PARTICIPA

viernes, 22 de mayo de 2020

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext


Enviado desde mi iPad

No hay comentarios:

Publicar un comentario

Danos tu opinion, enriquece el post.